Risk of recurrence when cutting into intramucosal (pT1a) cancer from the cutting-plane side during gastric endoscopic submucosal dissection.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 26 6 2020
medline: 16 2 2021
entrez: 26 6 2020
Statut: ppublish

Résumé

During endoscopic submucosal dissection (ESD), procedural difficulty and poor visibility of the cutting plane sometimes cause the operator to cut into the lesion from the cutting-plane side, making the vertical margin positive (VM1) or unclear (VMX). In the present study, we evaluated the risk of recurrence of gastric cancer with VM1 /VMX after ESD. In total, 1723 consecutive gastric cancers treated by ESD at Osaka International Cancer Institute from July 2012 to December 2017 were included in this retrospective cohort study. Among them, 231 submucosal or more deeply invasive gastric cancers were excluded because nontechnical factors may contribute to VM1 /VMX in such lesions. To quantify the risk of cutting into cancer from the cutting-plane side during ESD, the proportion of lesions with VM1 /VMX among the pT1a gastric cancers treated by ESD was calculated. The proportion of recurrence among these cases was calculated after exclusion of lesions with positive lymphovascular invasion or a positive horizontal margin in order to eliminate the obvious risk factors for recurrence. Among 1492 pT1a gastric cancers treated by ESD, 28 lesions (1.9 %; 95 % confidence interval [CI] 1.3 % - 2.7 %) histologically showed VM1 /VMX. No local recurrence (0.0 %; 95 %CI 0.0 % - 12.2 %) occurred among 23 cases. The median follow-up period was 41 months (range 10 - 84 months). No local recurrence was detected in pT1a gastric cancers after VM1 /VMX resection by ESD. Surveillance endoscopy could be adopted for such cases without additional surgery.

Sections du résumé

BACKGROUND
During endoscopic submucosal dissection (ESD), procedural difficulty and poor visibility of the cutting plane sometimes cause the operator to cut into the lesion from the cutting-plane side, making the vertical margin positive (VM1) or unclear (VMX). In the present study, we evaluated the risk of recurrence of gastric cancer with VM1 /VMX after ESD.
METHODS
In total, 1723 consecutive gastric cancers treated by ESD at Osaka International Cancer Institute from July 2012 to December 2017 were included in this retrospective cohort study. Among them, 231 submucosal or more deeply invasive gastric cancers were excluded because nontechnical factors may contribute to VM1 /VMX in such lesions. To quantify the risk of cutting into cancer from the cutting-plane side during ESD, the proportion of lesions with VM1 /VMX among the pT1a gastric cancers treated by ESD was calculated. The proportion of recurrence among these cases was calculated after exclusion of lesions with positive lymphovascular invasion or a positive horizontal margin in order to eliminate the obvious risk factors for recurrence.
RESULTS
Among 1492 pT1a gastric cancers treated by ESD, 28 lesions (1.9 %; 95 % confidence interval [CI] 1.3 % - 2.7 %) histologically showed VM1 /VMX. No local recurrence (0.0 %; 95 %CI 0.0 % - 12.2 %) occurred among 23 cases. The median follow-up period was 41 months (range 10 - 84 months).
CONCLUSIONS
No local recurrence was detected in pT1a gastric cancers after VM1 /VMX resection by ESD. Surveillance endoscopy could be adopted for such cases without additional surgery.

Identifiants

pubmed: 32583395
doi: 10.1055/a-1173-8575
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

833-838

Commentaires et corrections

Type : CommentIn

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Auteurs

Hiroko Nakahira (H)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Takashi Kanesaka (T)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Noriya Uedo (N)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Masayasu Ohmori (M)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Hiroyoshi Iwagami (H)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Noriko Matsuura (N)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Satoki Shichijo (S)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Akira Maekawa (A)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Sachiko Yamamoto (S)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Yoji Takeuchi (Y)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Koji Higashino (K)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Masanori Kitamura (M)

Department of Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.

Shinichi Nakatsuka (S)

Department of Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.

Ryu Ishihara (R)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH